Potential Medication Incompatibilities In Pediatric Oncology Prescriptions
Palavras-chave:
Drug Incompatibility, Oncology Service, Intravenous infusions, Pediatric, Patient Safety.Resumo
Introduction: Pediatric oncology patients have a limited number of venous access routes and need a large number of drugs during hospitalization. This study evaluates potential MI in pediatric oncology prescriptions and identifies possible factors associated with the risk of their occurrence. Methods: Cross-sectional study that evaluated prescriptions from a universitary and tertiary hospital from december 2014 to december 2015. The association between the variables and the risk to potential incompatibilities between drugs was determined by Student’s t test and Pearson’s chi-square, considering p<0.05 significant. Odds Ratio was calculated considering a confidence interval of 95% to each drug. Results: 385 prescriptions were evaluated. The average age from 124 patients was 9.22 years old (SD = ± 5.10), being 50.65% male. The most frequent diagnosis and reason for hospitalization were the leukemias (27.30%) and chemotherapy administration (36.10%). The fully implantable catheter was the most commonly used venous access, in 61.30% of patients. In 87.5% of prescriptions there was the possibility of MI, and a total of 2108 incompatibilities were found, considering 300 different combinations between two drugs. Age, diagnosis, reason for hospitalization and type of venous access were presented as risk factors for potential incompatibilities (p<0.05). Some of the drugs that presented higher risk to potential incompatibilities were: leucovorin, sodium bicarbonate, cefepime, diphenhydramine,dimenhydrinate,hydrocortisone and ondansetron with significant Odds Ratio. Conclusions: the possibility of MI in prescriptions of pediatric oncology patients is frequent. Thus, the identification of risk factors may contribute to patient safety and rational use of drugs.
Downloads
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Clinical and Biomedical Research

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
- Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).